Literature DB >> 24102512

Association of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis.

Petra Bergström1, Malin von Otter, Staffan Nilsson, Ann-Charloth Nilsson, Michael Nilsson, Peter M Andersen, Ola Hammarsten, Henrik Zetterberg.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron syndrome influenced by oxidative stress. The transcription factor Nrf2 and its repressor Keap1 constitute an important defence system in cellular protection against oxidative stress. Here we hypothesize that common genetic variations in the genes NFE2L2 and KEAP1, encoding Nrf2 and Keap1, may influence the risk and phenotype of ALS. Five hundred and twenty-two Swedish patients with sporadic ALS (SALS) and 564 Swedish control subjects were studied. Eight tag SNPs in NFE2L2 and three tag SNPs in KEAP1 were genotyped by allelic discrimination and three functional NFE2L2 promoter SNPs were genotyped by sequencing. One NFE2L2 haplotype (GGGAC) was associated with decreased risk of SALS (OR = 0.62 per allele, p = 0.003) and one haplotype in KEAP1 (CGG) was associated with later SALS onset (+3.4 years per allele, p = 0.015). When stratified by subgroup, one haplotype in NFE2L2, GAGCAGA including three functional promoter SNPs associated with high Nrf2 protein expression, was associated with 4.0 years later disease onset per allele in subgroup ALS (p = 0.008). In conclusion, these results suggest that variations in NFE2L2 and KEAP1, encoding two central proteins in cellular oxidative stress defence, may influence SALS pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24102512     DOI: 10.3109/21678421.2013.839708

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  13 in total

1.  RBM45 Modulates the Antioxidant Response in Amyotrophic Lateral Sclerosis through Interactions with KEAP1.

Authors:  Nadine Bakkar; Arianna Kousari; Tina Kovalik; Yang Li; Robert Bowser
Journal:  Mol Cell Biol       Date:  2015-05-04       Impact factor: 4.272

Review 2.  Functional polymorphisms in Nrf2: implications for human disease.

Authors:  Hye-Youn Cho; Jacqui Marzec; Steven R Kleeberger
Journal:  Free Radic Biol Med       Date:  2015-06-25       Impact factor: 7.376

3.  Resveratrol, Endocrine Disrupting Chemicals, Neurodegenerative Diseases and Depression: Genes, Transcription Factors, microRNAs, and Sponges Involved.

Authors:  Hai Duc Nguyen
Journal:  Neurochem Res       Date:  2022-10-16       Impact factor: 4.414

4.  Integrative Analysis of Motor Neuron and Microglial Transcriptomes from SOD1G93A Mice Models Uncover Potential Drug Treatments for ALS.

Authors:  Elif Kubat Oktem; Busra Aydin; Metin Yazar; Kazim Yalcin Arga
Journal:  J Mol Neurosci       Date:  2022-09-30       Impact factor: 2.866

5.  Research for type 2 diabetes mellitus in endemic arsenism areas in central China: role of low level of arsenic exposure and KEAP1 rs11545829 polymorphism.

Authors:  Chenlu Fan; Zaihong Zhan; Xin Zhang; Qun Lou; Ning Guo; Mengyao Su; Yue Gao; Ming Qin; Liaowei Wu; Wei Huang; Meichen Zhang; Fanshuo Yin; Yanhui Wu; Jingbo Pi; Yuanyuan Xu; Yanmei Yang; Yanhui Gao
Journal:  Arch Toxicol       Date:  2022-04-14       Impact factor: 6.168

Review 6.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

7.  Genetic Variations and mRNA Expression of NRF2 in Parkinson's Disease.

Authors:  Caroline Ran; Karin Wirdefeldt; Lovisa Brodin; Mehrafarin Ramezani; Marie Westerlund; Fengqing Xiang; Anna Anvret; Thomas Willows; Olof Sydow; Anders Johansson; Dagmar Galter; Per Svenningsson; Andrea Carmine Belin
Journal:  Parkinsons Dis       Date:  2017-05-02

8.  Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy.

Authors:  Ana I Rojo; Marta Pajares; Angel J García-Yagüe; Izaskun Buendia; Fred Van Leuven; Masayuki Yamamoto; Manuela G López; Antonio Cuadrado
Journal:  Redox Biol       Date:  2018-07-11       Impact factor: 11.799

9.  ALS-FTLD associated mutations of SQSTM1 impact on Keap1-Nrf2 signalling.

Authors:  Alice Goode; Sarah Rea; Melanie Sultana; Barry Shaw; Mark S Searle; Robert Layfield
Journal:  Mol Cell Neurosci       Date:  2016-08-20       Impact factor: 4.314

10.  Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes.

Authors:  Marta Pajares; Natalia Jiménez-Moreno; Ángel J García-Yagüe; Maribel Escoll; María L de Ceballos; Fred Van Leuven; Alberto Rábano; Masayuki Yamamoto; Ana I Rojo; Antonio Cuadrado
Journal:  Autophagy       Date:  2016-07-18       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.